ASTECPesticides & Agrochemicals
Astec LifeSciences Ltd — Cash Flow Statement
₹540.60
-7.01%
Astec LifeSciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Issuance Payments Of Debt | 63.28 Cr | 101.02 Cr | 60.65 Cr | 92.03 Cr | — |
| Net Short Term Debt Issuance | -26.95 Cr | -4.01 Cr | 44.75 Cr | 92.03 Cr | — |
| Net Long Term Debt Issuance | 90.24 Cr | 105.04 Cr | 15.90 Cr | 0.00 | — |
| Long Term Debt Payments | -60.76 Cr | -43.96 Cr | -125.70 Cr | 0.00 | — |
| Long Term Debt Issuance | 151.00 Cr | 149.00 Cr | 141.60 Cr | 0.00 | — |
| Investing Cash Flow | -15.23 Cr | -135.18 Cr | -112.51 Cr | -103.87 Cr | — |
| Interest Received Cfi | 0.79 Cr | 0.23 Cr | 4.09 Cr | 0.33 Cr | — |
| Net Investment Purchase And Sale | -0.17 Cr | -0.28 Cr | -0.11 Cr | -0.34 Cr | — |
| Net PPE Purchase And Sale | -15.85 Cr | -135.14 Cr | -116.48 Cr | -103.85 Cr | — |
| Sale Of PPE | 5.97 Cr | 0.36 Cr | 0.78 Cr | 0.12 Cr | — |
| Purchase Of PPE | -21.82 Cr | -135.50 Cr | -117.26 Cr | -103.98 Cr | — |
| Operating Cash Flow | -8.40 Cr | 10.22 Cr | 74.66 Cr | 23.60 Cr | — |
| Taxes Refund Paid | 4.99 Cr | -1.97 Cr | -4.89 Cr | -29.15 Cr | — |
| Change In Working Capital | 26.53 Cr | 10.49 Cr | -5.91 Cr | -112.39 Cr | — |
| Change In Other Current Liabilities | -0.81 Cr | -1.51 Cr | -1.81 Cr | 9.41 Cr | — |
| Change In Other Current Assets | 3.30 Cr | 15.62 Cr | -2.81 Cr | -15.31 Cr | — |
| Change In Payable | -7.75 Cr | -88.80 Cr | -14.28 Cr | 60.72 Cr | — |
| Change In Inventory | 15.87 Cr | 98.91 Cr | -108.80 Cr | -83.14 Cr | — |
| Change In Receivables | 16.15 Cr | -13.53 Cr | 121.72 Cr | -83.77 Cr | — |
| Other Non Cash Items | 35.89 Cr | 25.07 Cr | 16.67 Cr | 8.79 Cr | — |
| Stock Based Compensation | 0.03 Cr | 0.30 Cr | 0.33 Cr | 0.10 Cr | — |
| Provisionand Write Offof Assets | 20.22 Cr | 1.80 Cr | 0.84 Cr | 2.32 Cr | — |
| Depreciation And Amortization | 43.71 Cr | 36.25 Cr | 33.65 Cr | 34.36 Cr | — |
| Amortization Cash Flow | -0.05 Cr | 0.03 Cr | 0.80 Cr | 0.70 Cr | — |
| Depreciation | 43.77 Cr | 36.23 Cr | 32.86 Cr | 34.36 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 3.23 Cr | -0.10 Cr | -1.51 Cr | -1.51 Cr | — |
| Gain Loss On Sale Of PPE | -2.02 Cr | 0.11 Cr | 0.52 Cr | -0.01 Cr | — |
| Net Income From Continuing Operations | -140.99 Cr | -61.75 Cr | 34.95 Cr | 121.13 Cr | — |
| Free Cash Flow | -30.22 Cr | -125.28 Cr | -42.60 Cr | -80.37 Cr | — |
| Repayment Of Debt | -60.76 Cr | -43.96 Cr | -125.70 Cr | 0.00 | — |
| Issuance Of Debt | 151.00 Cr | 149.00 Cr | 141.60 Cr | 92.03 Cr | — |
| Issuance Of Capital Stock | 23000.00 | 0.08 Cr | 0.13 Cr | 0.30 Cr | — |
| Capital Expenditure | -21.82 Cr | -135.50 Cr | -117.26 Cr | -103.98 Cr | — |
| End Cash Position | 0.58 Cr | 0.47 Cr | 0.47 Cr | 0.55 Cr | — |
| Beginning Cash Position | 0.47 Cr | 0.47 Cr | 0.55 Cr | 0.34 Cr | — |
| Changes In Cash | 0.10 Cr | -19000.00 | -0.08 Cr | 0.22 Cr | — |
| Financing Cash Flow | 23.73 Cr | 124.96 Cr | 37.77 Cr | 80.48 Cr | — |
| Net Other Financing Charges | -1.00 Cr | 50.00 Cr | — | — | — |
| Interest Paid Cff | -38.55 Cr | -23.20 Cr | -20.07 Cr | -8.91 Cr | — |
| Net Common Stock Issuance | 23000.00 | 0.08 Cr | 0.13 Cr | 0.30 Cr | — |
| Common Stock Issuance | 23000.00 | 0.08 Cr | 0.13 Cr | 0.30 Cr | — |
| Cash Dividends Paid | — | -2.94 Cr | -2.94 Cr | -2.94 Cr | -2.94 Cr |
| Net Other Investing Changes | — | -0.28 Cr | -0.11 Cr | — | 28.87 Cr |
| Purchase Of Investment | — | -0.28 Cr | -0.11 Cr | — | -0.03 Cr |
| Gain Loss On Sale Of Business | — | 0.00 | 0.00 | 0.00 | -0.25 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | -1000.00 | — | -0.03 Cr |
| Short Term Debt Issuance | — | — | 44.75 Cr | 92.03 Cr | — |
| Common Stock Dividend Paid | — | — | — | — | -2.94 Cr |
| Gain Loss On Investment Securities | — | — | — | — | -0.25 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Astec LifeSciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.